You are on page 1of 15

c

cc
c   c

cccc

c !c
c

"#c##$c %c c"&c &"c c c '()'(**(c

c c c %cc +c+c)c c c '()'((,*c

%cc cc +cc c c '()'(**-c

%cc ."/c#c+cc c '()0'*10c

%c &c."c+cc c c '()'2-3,c

c c c %cc #c4c 5c c c '()'(**2c

6cc c %cc *7 0c

+"##c c %cc 8"c6#"cccc

c c c c 97"c:c 8#;c

c c %cc 
7c,3,1c "c5cc7"c"c 8#c

< c %cc


!c"#c#c
Purinex, Inc.c cc
 c  c ccc c cc  c
c

c  c   c  c    c    c  c c  


c c  c   c c

c  c c
c  c c

c c c


c  c c c

c
 c c

c c
c   c   c   
c  
 c    c  
c
c    !c


c  cc

Purinec c 
 c   c   c

c  c  c  

c  c c
c  c

   c c c c


c c  c
c

c   c c c c
c



c c
cc    c  c   c  c   cc
c c

  c

c 
c c  
c agonists (activators) c antagonists (blockers)c  c   c

  c 
c c
c  c  c c  "c   c  c   c c
c   c c
c

 c   
c

c  c c 
  c    c 
c  c  c  c

   c   c
 c

c c
c c

c
c
c
c c


c
cc c  c  c c 

 c  
c
c   c c
 c
c c 


 
c  c
c   c
  cc  
c    c  
c  c
c   c   c

c c
c


c c 
c c c c c
c 
c c c
c  c

 c c   c c#$c c cc   c


c c
c cc  c

  c
 
 c 
c c  c c c
c  c% 
c
cc&'c "c

 c c
 c  
c   c c  cc 
c  
c c 
ccc c

 c
c  "c c  c
 
 c 
c c
c  c c cc 
 c c

  
c c c
 c()c

c  c c  c c
c  c  cc

   c  c c c  c  c c


 c c  
c  c c  c c


 
c c 
c cc   
c c  
c c c
c  c

c  c  c

ccccccc*+,c c c  c c
c


c 
c c  

c

c c 
 
c  c  c c  c    c  c



c c 
cc 
c  c c  c
c c 
c c c c
v
 c    c  c


c c  c c   
c c c   c
c 
c c
c

 cc 
c  
c c
 c c
c c
 c  c

- c  c


 
c   c cc
c

c c  c
c c 
c


c

  c  c
c  
c  
c 
 c
c .
c 

c c ,c  c c   
c 
 
c

  c

c  c c
c   c c  c c 
c   c c   c 
 c c

 
c c
c c c

c
c  c c 
c

 c  c c c/'c cc c

 c c0 c
c
c c
c1 c  c c 
c c
c

cc
c c c

 
 c
c 
c


c
c
c cc c   c  c 
c c c c

 c


c  c
c  cc  
c c

c c  c
c
c

 cc 
c  c c cc 
c c
c
cc
c
c c
c
c

c

 c  c c
c c  c  c  c


c 
c  c c  c   c  c c c

  c
  c
 c  c c  c  c c c   c 
c c  c

c
c   c  c

 
c

 c  c c c/)22c cc c
 c c* c  c
c c c
c

 c  
cc  c
c cc

c 3 c
c c
c c
c   c  c c  c c
c c
c  c
 c  

c


c  c 4 c 
  c

c 5  c
c   
c  c c  c

c * c  c + c , 

c #*+,$c c
c .
c 

c
c   c
c  c  c  c

c  c
c  c c c  c   c  c 
c c
c  c c c  

c  c

  c c 


c  c
c c 
cc
c 
c
c4 
 c
c c

  c

c+  c  c

c
c c62c c*+,c

c

c&(c c&'c c c

  c  
ccc cc c7c c c  c  ccc
c c&(c

c&'c c0 cc c6c c  c  


ccc,
c c


c

c)c
c
c&2c
c c c

c 
c  c

cc

 c c c


c

þ
 c
c c   c c c c c 
c c 
 c c  c
c

*+,c

c,c  cc
c c c c

c c
c c
c  c
c c cc

 c
c c

cc
 c c c
c
c  c

c

c  cc*+,c

c  c cc*+,c


ccc c c c
c4 ccc c-c c

+ 
c #-8+$c  
c ,  c
c 
 c 8c  "c -8+c   c c 
 c

 c c '2c 


c c
c  
c  c  c c  c c 
 c  c  c
c

 
c  c 5  c   c
c c 
c c
c  
c % 
c 9 c #%9$c c

c622&c
c 
c/::2c c c  c
c cc c  

c  c c

c  


c c
c c;)c
c c
c

 c-8+c 
c

Problems of Purinex

c   c  c c    c  "c %*0c 9 c 3!c c  


c
c 
 c c


 c 
c c 1 c 
 c   c  
c c
c 
c  c
c
 c 
c

c
 c
 c c  c
c  c
c c c c
c  c  c
cc

 c c
c


c c c c
c  "c 
c c cc

   c c c 
c c    c  cc  c c
c 
c c c

 c  c c c /;22222c c c c  c c   c c


c   c c  c
 c

 c 5
 c   c c
c   c c 
c /<2222c %c  c

c    c  c

 c c  c
c  c
c  c c
c&&c
c5  c   ccc 

  c c 


c  c
c c
c
cc c
c c c c-c c

+ 
c#-8+$c c c
c c c
 
c c 
c c c
c


c c

 
c c c= 
c
 c c c  cc
c
 c c-8+c

,  c
cc
c c 
c. 
c c c
c cc c  

c  c

c 
cc  c

 c c/:7;c cc

c,c  c c c


 c
 c   c cc1 c
 c  c

c   cc
c   c c
c c
c
 c
c c c
c    c  c

c

V
  c  
c  c    c  c  c  
c 
c  
c 
c c  c

  
c 
c cc cc c
 c c-8+c  c3 c
cc
 c


 c   c c 
c c  c  c


c c  c  c 
c  
c  c



c c 
cc 
c c c
cc c c


c c c  c   c
c

 c/&2:c c 
c,
c c  c
c c   c/:2c c 
c
c

c c

c
c c<2c
c 
c

c
c 
c c c
 c c  c c c

 c    c
c  c  c
 c   c  c #0$c   c c c
c  c c 
 c c

4 
c  c
c  c
c   c c
c 
 c 
c 
c c c
c
 c 
 c
c


 c "c 
ccc

 c4 
c

cc   c0c  
c,
 c
c

  c
c c c
c
c c c 
c
 cc
c 
 c c c c

c
c  c

c c
cc  cc
c%*0c

 c

c
c  c  
c  c   c  c c  
c  c  c c

  
c c  
c c c
c cc  c  c

cc

c c c c c*+,c  c  c   c  c


c 
c 
c c  

c

c 0 c

c
c
c &2&)c c
c  c c  c  c   c

c
c 
c   c

  c

c c
c 
c   c
c c
c
c c
c'2c
c c
c
c

 c  c 4 c


c  c c c   c
c 
c ,  c
c * c  c + c

, 

c #*+,$c c
c c  c

c 
c
 c  c
c   c  c  c

  
c 

c

c c c)c
c&2c
c c
c c c c
c  cc

 cc c
 c c
c  
c c
cc
c c  c  c


c c
c
c cc
c  cc

c  c  


c
c
c%*0c  c c c
c    c  c

c cc

c  c, c c


 c c
  c   c 
c c
c  c
c c c

 c  c
c c

c 
c c

 c  c c
c
c  c,  c
c

  c c  c
c 
 c c c
c 
 c c  c
c c  c 
  c    c
c

ã
  c c
c c  c
c 
 
c c  
c  c  c   
c
c

c  c

 c  c c *+,c c


c  c 
c c  c   c
c   c  c
c

 c

c 
c c  
c  c c 
c c   c  
c
 c
c   
c

 c
ccc c  c c c c c c c c
c
c
c

›omparison among the options and ranking in terms of risk and return

c %*0c c   c
c 
c 
  c    c c c c
c   c  c
c


 c  c 
 c  c  c
 c 
c
c   c
c c  c
  c c c
c


c

c  cc3!c cc

 c c  c c c 
c c
c


 c  c c  c 
c  c c 
c c 
c
c  c  c 3!c c
c c

  c c c 


c
c  c c c c cc c
c c
c 
c

c c

 c
c 
c 
c
c
c  c

c * 
c c  c 

 c  c  c  c    c  c /&2c  c c c 
c

 c c  c   c c


c  c
c&<<<;c
c c&(:(cc#&2 ><2222$c

 c
c 1 
c
c (c 
c
c   
c
c  c 
c /&2c  c c 
 c 4 
c  c

   c c
c
c
cc c 
c c 
c c c c
c?
c


 c c c
cc c 
c c/&)c c c   c c c   c

 c c 
c 
 c c  c 

c c c  c 
c 
 c c  
c c

 c
c  c

c c 
 c  c    c  c  c 
c   c c  c

 
 c
c c 
c  c  c  c 3!c #%*0$c c
c   c 
c  c


c c c 

c  c c  c 
c
c
 
c c  c c


cc   
c c c
 
c cc c c c

c

c

 
c c c c|  
           

          


                 

     c c c


c c c c c 
c  c  c c

c
c   c cc
cc
c c
c
c
 c cc c
c
c
Ä
0 c
c
c  c3!c c

c c c 
c
 cc
c  
c
c c

c c cc cc&2c


c

c + c
 c c
c c
c c
c
 c c c
c c 
c c c

   c    c  c  c 1 
c  c
 c  c  
c 
c  c c  
c  c c  c


 c&&c
c,  c   c cc
 c c c c
c
c c

c c

# c 
 c  $c c
c c
c  
c
c    c  c c 

c c
c 

c

c c c&2c


c c
c c
c   "c 
c  c
c
 c
c
 c
c

c   c   
 c  c c c /6)c  c  c
c   "c  
c  c c
c

 
c c
c
c
 c 
c0 c
c
c c c   c "cc c c c

1 
c c
cc
c  c&&c
c&6c
c
c
c  c c1 
c
c c c
c

 c   c 


 c    c  c c 
c
c  c c  
c c  c   c
c

  c c
c
c c
c
c  c
c
  c+  c c  c c c
c

   c  "c 
c  c  c 
c
c  c c  
c 
c  c c
c  
c

 c c c c


 c
c cc
 cc c 
c c   c c   c c

 c
c1 
c/:c c c c c
 cc cc/)c c c
c 
c   c  
c

c
c 
c
c c
cc c
 cc c c
 c c c
 c
c c

c 
c

c   c c ccc    c 
c3 c c
c
c 
  c
 c

c  c 
c c 
 c  c c  c c
c  c c 
 c 
 c

 c c
 c cc c
c
c
 c c=  
c6cÎ     

       !c


c  c

c
c c &2c   c   c c
c


 c c
 c;c
c

c 
c 
 
c c   c  c c   
c 
 c 
c 
 c  c   c


c  c c
c c
c 
c c
c   c c
c %*0c  c
 c 
c
c

  c c
c  c
c  c c  c  c c
c  c  c 
c 
 c  c ,  c


cc1 
c c
c  c/6c c c   c c c c1 
c c c   c

r
 c  c
c((c
c 
c c
c c
c c c
c 
c
 c  c c

% c
c
c
 c
c c c c  c 
cc c c c
c c

c
c  
c
ccc
c c c c3!c 
c
c
cc  c cc
c
c


c  c c
 c
c  c 
c
cc
c c
c c
c

c c c c 


c  c c   c cc
c c
cc cc cc

c 1 c  c


c 
 c
c   @c
c  
c   "
c c 
c    c c  c

* 
 cc c 
c c/&;)c c cc 
c
c   c c
c
 c  c


c  
c  c
 c 
c 
 c 
c c 

c
c 
 c   c 
c

?
c 
c   c cc
cc
c c
c  c 
c
c
c  
c c

 c
c
c  c c c c
c
cc

 c cc c
c

 c
 c c c  cc c
c c
c c
c


 c  c c  
c  c c 
c 
 c  c  c c 
c   c c  c c

 c
c c
 c c
c
c 
c c c c
c
c   c c c
cc
cc

c  c 
c
c 
c 
c 
c c   c 
c c c  c  
c

  c 
c c c c, c   c c1 
c c
c 
 
c
c 
c 
c c

  c  
c  c
c 
 c ,
 c    c  "c  
c  c 
c


 c
c 
c 
 c
c
c   c c 
 c c 
 c 
c
 c 
c


 c  c   c  c 
c c  
c * 
 c  
c c
c   c c 
 c

 
cc
 c c cc622(c c622'ccc c1 
c c
 c

c3!c c
c

c
c   
c  c c
c  
c  c
c c 
c  c
c 
 c  c

,
 c
c

 c
 c c
 c c c
c
c c
c

c c c c
c


c c  4  c c  c
c 
c 
 c  c c   c  c   c

 c    c 
cc

 c  cc c


c c c
 c c
c
 c c?
c
 c c

 c
c   c  c 
 
c   c #/&2 $c
c  c    c  c 
 c (c 
c
c

4
c
c c
c  c c cc c c
c  
cc c 
c c c

 c 
c
cc
 c

c c
c
 c c 
c c
 c c
c

 cc c


cc c3 c
c c  
c
c
c
 cc   c c

c
c c  
c c
c  c 
c 
c 
 c 
c c  

 c 
 
c

1
c
c  cc c c
 
cc   c c
c
 c 
c c

c
c
c c c c
 c c
c c
 
c c  c
c 
c c
c 
c

 c  c c


c%*0c c c1 c,cc
c 
c  c c   c c  c
 c
c

c   
c
 c
c
c  c
c
c cc c c c 
c c

c  c 
cc

c 
c   c c   c  c = c   c 
c c  c
c  c c 

c  c

 
c c
c
c
 @c c
cc
c c c c c   c  c

,  c 
c c 1 
c  c
c  c
c c /6 c  c c   c    c  c   c


c ((c 
c c , c /6c  c c 
 c
c 4 
c
c   
c c  c

 
c ,
 c   c 
c  c
c  c  c  c 
c
c   "
c  c

c c ! c  


c
c  
c c  c  c c
c   c 
 
c c   c


cc4 c c c
c c
 c c
c  
c c c c  cc
c

5  c
c
c  c 
c
c   
c   c  c c    c  c c c  c

 c
c
c
 c ccccc

Èinancing options chosen by us

 c c  c c  c  
c
c
c %*0c
c   c
c  "c  
c c   c


c
 cc
c 
c c
c

c c
c c<c
c
cc
 c
c
c

  cc cc


c 
c  c
c
c c<c
c c
c cc c
c

 c<c
c c
c  

c

c
 c c c c
 c
c
c
c  c
c c

c  
 c c 

c c 
 c  c  c
c c c ;)c 
c  c

c

   c c cc
 c
c
 c  cc

(
,
 c
c c c c c c c
c
 c#/6)c $c c c
c c c


c  c    c c
c c  c
c 
c c 
c 
 c  c   c  c
c

  c
c  
c    c  c c  c
c c    c   c  c 
c

 c
c c
c
c c c
 c
c c c c
c  cc c 
c

* c
c c
c c c

c c  
c c   c  c c
c/:c  c cc

cc/)c c
c  c c c
c c  c c c 
c 
cc

,cc
cc c c
c c
c
 cc c 
c c c
c
c
c


c
c  c /&2c  c  c c ?
c %
 c  c % 
c    c c /;22222c c

c c c c c


c c
c 
 c c
c&6c
cA
c
c
  c   c

c/&2c c   c c c


c 
 c
c
 c  c 
c c/<2222c#
c
 c
c


c c  c c 
c 
c /&22222$c  c 
c &'c c  c  c
c  c

 c  c c  c   c ,c c  c



 c  
c
c  c  c c   c

  c  c
c
c &2&)c c
c  c  c   c  
c
c 
c   c

% 
c
c c c   c 
c 
 
c  c  c
c


c c  
c c

 
c c c
c


c c cc  
cccc  c
  cc c c/&2c

 c c c


c
 c c c   
c c c
c c
c  
c
c c

 c 
c c
c
c cc
 c
c c c 
ccc

,
c   c c
c c
 c
c
 c c c(c
c
c
c c
c c

<c 
c c c
c   
c c 
 c  c 
c  c  c c  
c  c  c  c

 c
c c c
c c c1 
c  c
c c<c
c c c
c
 c c

 c
c  c
c 
c
c  "c     c 

c  c
c  c 
c c  c  c #/&2c

 $c c
c
 c
c  
c
 cc c  cc

* c
c c
c  c

c  c c 
 c  c c  c

  c
c
c
c c c c
 c
c c622(c
c622'c&2c  c

  
c 
 c  c 
 c ;c 
c #=  
c 6$c  c
c c V c c  
c ,  c
ð

 c  
c  c "c 
cc
 c
c
c c#=  
c'$c c
c c

 

c  c    c
c 
c 
c
c c c
c  c  

 c c
c  c

?
c 
 c  c c  c  c

c c 
 c 

c 5  c c

 c c
c
 c  c c   c c
c c cc cc&2c
c

 c    c  c  c


c  c  c
 c 
c 
 c  c  c  c  c


 c,cc
c   cc
c c c
 c c
cc
 cc4 
c

 c
 c  c  c c
cc

0 c c
c   c c 
c 
 c   c c    c  c c
c 
 c c

  c  c c c  c 


 
c   c 

c c  c c  c



c c  c 
 
c c c  c   c
c
 c  c  c  c

 
c

c%*0cc c c1 c,c
c
 c c c
c c
c  c c
c c
c


c c   c  
c c  c  c %*0c c   c
c  c c 
 c  c  c


 c 
c c c
c
c c
c c cc
 c c c c 
c

 
c  c
c c
c c  c3 cc cc
c cc  c

 c 1 c 
 c  c  c
c  c
c   c  c
c  c 
c  c c 
 c c


c 
 
c  c
 c  c

c c
c  c  
c c
c  c 9 c

 
c
c  c  c c
c  c c  c  c
c  
c  c 
 
c  c c


 cc

?
c 
 c 
c c    c  c
c  c

c
c  c  
c 
c c

  c  c  c
c  c  c  c  
 c
c 
c    c c
c c
 c

 c 
c 
c 
 c  c  c c c 3 c  
c c
c 
c 
 
c c

 

 c c
c c 
c
 c 

c c
c c c
c
c

cc c

c

 c  c
c c   c  

c  c
 c c    c  c c  c
c 
 c
c


 c c c
c
c
 
c c c
c  c

c
v
ualitative factors under consideration

cc c 4 

c
c

cc c c  
c c
 
 c c  c

 c  c 
 
c 
 c c   
c c   c  c
c    c

  c c
c
 c 
c  cAcc c

c
c
c   c  c c

c c   c c
c c
c
 cventure capitalc cseek for partnership deal in

the sepsis drug. 0 c   


c  c c   c   c c
c    c 
c  c


 c cc

c c Bc

Èinancing Options

1).›ontrol and Restrictions Issue

c 

 c  c  c   c  c    c  c 
c
 c
c 
 c

 c  c c  c


 c
c c
 
c c
c cc c
c c
 c


c 
 c  c   c  c    c c 
c 
 
 c c
c  c

c
c  
c 
c

 
c  cc  
c c
c
c c 
c  c4 c
c c
cc

c
 c  c 
c
c
c

 c
c cc
c
 c 
c
 cc

 
c   c   c c
c  
c

c  c    c  c  c
 c    c 
c

 cc c


 !c ccAc c

c
c
 c c
c
c 
cc
c c c

/&2c c c(c
cc c
c/6c c c  c c   c c c
c


 c c c
c
 !c
c c c c
c c c c  
c c 
cc


 c
 c cc

2). Possible Impact to Partnership Deal

,
c1 c
c

cc c
c
c
c  
c c
c    c 
c c

c   c    c 


c c
c
c   c 
cc c   c%*0c9 c

3!cc  c

cCc c c
c
 c  c c   c c
c c cc


 c  c c &2c 
Dc * c c  

c c  c
c

c
c  c c
c


 c c c cc 
cc/&&(c c
c/&6'(c c c
c
 c/&&(c

vv
 c c
 c cc c

c
c

 c  
c c
 c c c c

 c
c 
c
c  c c
c c
 ccc

V). Uncertainty in Partnership Deal

Ac  
c   c c
c  c 
c c   c c 
 c  c c 
 
 c c

   c  c c


c c c
 c c  cc
 c c c cc c

cc c 


c c c   c  cc c
c c  cc
 c c

 c c c

c
cc cc c
c 
c
c c

c

c
cc c<2c


c  
c

c
c  c c c  c  c  c c
c 
c  c
c
 c 
c  c 7)c


c 
c

c
c 
c
 c c  ccc 
cc c 

c

  
c 
c
c 
 c  c # $c c c
c c  c  c
c c  
c

    c   c Ac  c



c  c c  c 
 !c  c
 c 
c 
 c #/&2c

 $c c c
c c
c
 cc

c c
c  c 
c  
c
cc

Partnership Deal

1). Potential Revenue and Èinancial Package

c
 
c
c c c 
c c
c
c   c
 c c c  c

c

 c c

c cc c
c 
cc
c c c
c
c,c 

c c
c


c   c%*0c9 c3!cc

c

c
c  c c c 
c c c c

c /'c  c  c /)22c  c 


 c c  c c 
c
 c c  c

c
c c c
c 
c



c c
c  c
c
 c
c 
c c  c 
c c c  c
c 
c

 c c c
 c
 c cc

* 
 cc  c c
c
c
c
c
c    cc

c c cc


 c  cc    cc c c
c c
 c c c/)c  c 


c/&2:c c 
c&2Ec 
c c
c 
c c
 c
c/:c c 
c

/:2c c  
c c&6Ec 
c c c c c cc c c 
c


c c c

c
c c  c  c
c
 c
c  
c
c c
c c
cc c


c
c c   c c 
 
c c  
c  c c  c
c  c c
c  
c     c

c c  cc


cc  c c
c
 c  c
c  
c  c
ccc 
c

* c
c    c
cc c

c
c c c
c
c

c c
c c
cc  c

c c c c c  c


c c c
 c
 c cc

2). Biotechnology Development Risk

. 

c c  c c cc
 c c
 cc
 
c
c 
c

 
c  
c
c c 

c c  
c . 
c

c
c  
c
c  c c   


c   c c /:7;c  c # c 6222c  $c  c   c  c

c
c c


 cc c
c cc
 c
c
cc c
c c
c  c 
cc c c


c,c c
 c  cc c 
c c
c  c c c
c c

 c
c
 c

 c c c cc c

c cc
 c c c c

c     c  c
c  c c
c  c  c
c  c    c  
c  
c  c  c


c     c c c
c 
c 5  c
c   c  c  c    c
c  
c
c

  c  c
c  c c   c   c  c # 
$c  c  c 
 
c
c c  c

 c
c c  c
c c c
c
c

V). Potential IPO or Buyout Deal

,c 
 c  c  c 
c  c c c c c  c
c 
c  c c

   c
c    c c c
c

c    c c c    
c c
c  c  c


c  c
c 
c &&c 
c  c   c  
c
c  c 

c c     c  
c c

   c c
 c

cc c

c c
c
 c c c 1
c c c

c 
 c c    c  c    c c   c
c    c c 

 c 0c c  
c

  
c c cc

 
c
c
c    c

c  cc
c
 c c c

 c
cc
 c c c
c
c

 c 
c
c
c  c c
 c

cc

 c

c 
 c  c  c  c  c 
c 
c     c c  c c 
 c
c

vV
  c    c 
c4 c
c
c 
c c  c
c  c "c c c
c

c c

ã). Long-term Development ›ost

,
c 1 c   c c
c 
c  
c  
c c c  c c
c  
c c

  c c c 


cc  
c c
c  c,  c
c
c

c
c 
c. 
c

c  
cc
c c  c cc622(c 
c

c
c4 c/:7;c c# c6222c $c

c cc c  



c  cc0 c
c
c c   c  c
cc
c

/<2222cc
c#
c&22222cc
c c
c c  
$c cc c

c

 c c  c  
c  1
c  c
c  c
c  
c
c
 c  
c c   c c  c

5  c  c c  c



c c    c  c  c
c c  c  c c c

 
c
c 
c  c
 c c c
c  c
c 
c c 

 c

 c
c  c F  c
c c c c  c  
c  c
c  c    c
  c


c
 c cc
c
 c c c cc
c c
c 
c 
c    c

c
c
c  c c 
c     c c  c  c
c  c   c c  c
c

 c c 


c 
c 
c
 c c
c !c "c c c
c c cc

 c    c c  c

c    c c
c 
c 
c
c  c  

 c    c

 c
c
 c c c
c
 !c
c c c
 c  c
c c
ccc c

    c 

c c  c
 c  c
c  c
c  c c 
 c  
c
c 

c c



c     c c c 

 c 
 c  c  c  c    c
c  
c
c  c

 c c  
cc
 c c c  c   c
c 
c c
c c c 
c c

 c
 cc c c

 c c
c
c, c
c c c c
c  c c
c

  c  c 0c  

c c 

 c  
c c  c  c 
c c
c 
c

c c
c

 "cc